AstraZeneca To Inject $2B In US Cancer Biopharma
British giant AstraZeneca said Tuesday it will invest $2 billion in oncology specialist Summit Therapeutics and partner with the U.S. biopharmaceutical firm to boost its cancer treatment portfolio....To view the full article, register now.
Already a subscriber? Click here to view full article